Diabetes will affect more than 1.3 billion people by 2050, according to a systematic analysis published in The Lancet, marking a steep global rise from an estimated 830 million individuals living with the condition in 2026.
Most patients reside in low- and middle-income countries, with over 90% of cases classified as Type 2 diabetes, where the body fails to use insulin properly. Type 1 diabetes, the second most common form, stems from the immune system attacking insulin-producing cells.
Regional projections from the Global Burden of Disease Study 2021 show that nearly 17% of people in North Africa and the Middle East, and 11% in Latin America and the Caribbean, may live with the condition by mid-century.
In November, James Talarico was elected to the U.S. Senate. Talarico uses his experience living with Type 1 diabetes to advocate for lower insulin costs, joining New Hampshire representative-elect Stefany Shaneen, whose daughter also lives with the condition, The Conversation reported.
Transplanted insulin cells face immune rejection
Researchers are pursuing cures by growing insulin-producing cells in laboratories or taking them from deceased donors for transplantation into patients with Type 1 diabetes. Clinical trials show that most people who receive these transplanted cells either stop needing insulin or need much lower doses, which cuts their risk of deadly low blood sugar episodes.
The primary barrier remains the body recognizing the new tissue as foreign and launching an immune attack. This risk is magnified for Type 1 patients because their immune systems have already destroyed their own insulin-producing cells. While immunosuppressant medications help, the lifetime health risks of those drugs outweigh the benefits for most individuals.
Scientists are investigating modified cells engineered to evade immune detection before implantation. Other trials explore targeted medications designed to stop the immune response against insulin-producing cells without inducing generalized immunosuppression.
Teplizumab delays insulin dependency for years
Therapies that delay Type 1 diabetes progression by slowing the destruction of insulin-producing cells are already available. The drug teplizumab can delay the onset of insulin dependency by up to three years, giving children and families time to plan before daily injections and blood sugar monitoring begin.
In the United States, individuals with a family history of the disease can undergo screening before symptoms appear. Blood tests identify immune system markers attacking insulin-producing cells long before blood sugar levels rise. Such testing can be conducted at home or in a doctor’s office.
Because 90% of people diagnosed with Type 1 diabetes do not have an affected close family member, European experts are urging health authorities to roll out universal screening. Without broad access to testing, researchers estimate that more than 250 million people worldwide remain unaware they have Type 2 diabetes.
Remission and GLP-1 Discoveries
Clinical trials for Type 2 diabetes offer additional therapeutic options. A clinical trial published in October 2026 involving nearly 100 people with early-onset Type 2 found that over half of participants achieved remission six months after starting a low-calorie diet and supervised exercise program. A separate 2025 study showed that an artificial intelligence mobile application providing personalized lifestyle advice led to sustained remission in over half of participants for up to three years.
GLP-1 medications lower blood sugar and also reduce deaths, hospitalizations, and amputations in high-risk groups. Recent studies indicate these drugs can also prevent the onset of Type 2 diabetes in people with elevated blood sugar levels.
Global Inequities in Care Access
Global treatment disparities limit the impact of these scientific advances. Only about half of all people worldwide with Type 2 diabetes have access to necessary insulin, and GLP-1 therapies remain concentrated in high-income nations where costs are prohibitive. Screening and early treatment for Type 1 diabetes are also rarely available in low- and middle-income regions.
Questions cover Type 1 causes and insulin access
What causes Type 1 diabetes?
Type 1 diabetes is caused by the immune system attacking insulin-producing cells.
How does teplizumab help patients?
The drug teplizumab delays the progression of Type 1 diabetes by slowing the destruction of insulin-producing cells, postponing the need for insulin injections by up to three years.
What proportion of Type 2 diabetes patients have insulin access?
Only about one in two people globally with Type 2 diabetes can obtain the insulin they require, according to health researchers reporting on worldwide care disparities.
Founded in England in 1823 by surgeon Thomas Wakley, The Lancet remains one of the oldest medical journals still in publication. It is a weekly peer-reviewed general medical journal owned by Elsevier since 1991, with editorial offices in London, New York City, and Beijing.
What did Frederick Banting do with the insulin patent?
In 1923, Canadian scientist Frederick Banting sold the patent for insulin for one Canadian dollar, stating that the medication belonged to the world.
Worth a look